TENOFOVIR 300 MG — DIN 02512327
TENOFOVIR DISOPROXIL FUMARATE : 300 MG · SANIS HEALTH INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TENOFOVIR?
TENOFOVIR 300 MG contains TENOFOVIR DISOPROXIL FUMARATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02512327, held by SANIS HEALTH INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Aug-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Tenofovir Disoproxil cost around the world?
Tenofovir Disoproxil is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| South Africa | single exit price | 3 | 4 | ZAR███.██ |
9 pack listings across 8 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Tenofovir Disoproxil pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Tenofovir Disoproxil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Tenofovir Disoproxil, across 13 DINs, of which 13 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ANGITA PHARMA INC. | 1 | 1 | AG-TENOFOVIR | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-TENOFOVIR | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-TENOFOVIR | Sourceable in Canada |
| GILEAD SCIENCES CANADA INC | 1 | 1 | VIREAD | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-TENOFOVIR | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 1 | 1 | RIVA-TENOFOVIR | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-TENOFOVIR | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-TENOFOVIR DISOPROXIL | Sourceable in Canada |
| NATCO PHARMA (CANADA) INC | 1 | 1 | NAT-TENOFOVIR | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-TENOFOVIR | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | TENOFOVIR | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 1 | 1 | TENOFOVIR | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tenofovir Disoproxil |
|---|---|
| ATC code | J05AF07 |
| AHFS class | 08:18.08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02512327 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2512327 |
| Brand name | TENOFOVIR |
| Generic / active ingredient | TENOFOVIR DISOPROXIL FUMARATE : 300 MG |
| Market authorization holder | SANIS HEALTH INC |
| Health Canada schedule | Prescription |
| ATC code | J05AF07 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AF |
| Current status | MARKETED |
| Status date | 20-Aug-2021 |
| Original market date | 2021-08-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Tenofovir Disoproxil in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SIVEM PHARMACEUTICALS ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
13 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TENOFOVIR | 300 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02516276 |
| APO-TENOFOVIR | 300 MG | TABLET | APOTEX INC | MARKETED | 02451980 |
| AURO-TENOFOVIR | 300 MG | TABLET | AURO PHARMA INC | MARKETED | 02460173 |
| JAMP-TENOFOVIR | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02479087 |
| MINT-TENOFOVIR | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02512939 |
| MYLAN-TENOFOVIR DISOPROXIL | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02452634 |
| NAT-TENOFOVIR | 300 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | 02472511 |
| PMS-TENOFOVIR | 300 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02453940 |
| RIVA-TENOFOVIR | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02515156 |
| TENOFOVIR | 300 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02523922 |
2 · Same class — other molecules in ATC J05AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil | AG-TENOFOVIR · APO-TENOFOVIR · AURO-TENOFOVIR · JAMP-TENOFOVIR · +8 more | 13 | 13 | Yes |
| Entecavir | ACCEL-ENTECAVIR · APO-ENTECAVIR · AURO-ENTECAVIR · BARACLUDE · +6 more | 12 | 10 | Yes |
| Lamivudine | 3TC · APO-LAMIVUDINE · APO-LAMIVUDINE HBV · AURO-LAMIVUDINE · +4 more | 14 | 9 | Yes |
| Zidovudine | APO-ZIDOVUDINE · NOVO-AZT CAP 100MG · RETROVIR (AZT) · RETROVIR (AZT) 300MG · +1 more | 7 | 3 | Yes |
| Abacavir | APO-ABACAVIR · MINT-ABACAVIR · ZIAGEN | 4 | 3 | Yes |
| Tenofovir Alafenamide | VEMLIDY | 1 | 1 | Yes |
| Didanosine | VIDEX CHEWABLE DISPERSIBLE TAB 100MG · VIDEX CHEWABLE DISPERSIBLE TAB 150MG · VIDEX CHEWABLE DISPERSIBLE TAB 25MG · VIDEX CHEWABLE DISPERSIBLE TAB 50MG · +2 more | 9 | 0 | Not in Canada |
| Stavudine | ZERIT · ZERIT - CAP 15MG · ZERIT - CAP 20MG · ZERIT - CAP 30MG · +1 more | 5 | 0 | Not in Canada |
| Zalcitabine | HIVID TAB 0.375MG · HIVID TAB 0.75 MG | 2 | 0 | Not in Canada |
| Adefovir Dipivoxil | AA-ADEFOVIR · HEPSERA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TENOFOVIR called?
Also recorded in Canada as: emtricitabine 200 MG / rilpivirine 25 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Complera] (US), tenofovir disoproxil fumarate 250 MG Oral Tablet [Viread] (US), tenofovir disoproxil fumarate 150 MG Oral Tablet [Viread] (US), tenofovir disoproxil fumarate 200 MG Oral Tablet [Viread] (US), tenofovir disoproxil fumarate 0.04 MG/MG Oral Powder [Viread] (US), emtricitabine 100 MG / tenofovir disoproxil fumarate 150 MG Oral Tablet [Truvada] (US), emtricitabine 133 MG / tenofovir disoproxil fumarate 200 MG Oral Tablet [Truvada] (US), emtricitabine 167 MG / tenofovir disoproxil fumarate 250 MG Oral Tablet [Truvada] (US), efavirenz 400 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] (US), lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo] (US), efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] (US), doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Delstrigo] (US), lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Temixys] (US), tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] (US), emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Truvada] (US).
The same molecule, Tenofovir Disoproxil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Atenef | Latin | South Africa |
| Rizene | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.